MabThera nabs NICE nod for leukemia

The U.K.'s cost-effectiveness watchdog has recommended Roche's top-selling cancer drug MabThera as a first line treatment for the most common form of adult leukemia. NICE recommends that the National Health Service pay for MabThera treatment only in combination with two specific chemo drugs. Report